Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hydrophobic Interactions of Modified Coconut Oil and Pluronic 127 Enable Stable Formation of Bioactive Hydrogel for Onychomycosis.

Gels (Basel, Switzerland)·2025

Same author

The Effects of Encapsulating Bioactive Irish Honey into Pluronic-Based Thermoresponsive Hydrogels and Potential Application in Soft Tissue Regeneration.

Gels (Basel, Switzerland)·2025

Same author

Intra- and interobserver agreement of proposed objective transvaginal ultrasound image-quality scoring system for use in artificial intelligence algorithm development.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2025

Same author

Current trends in biopharmaceuticals production in Escherichia coli.

Biotechnology letters·2022

Same author

Contrasting opioid use for pain management in microvascular head and neck reconstruction: an international study.

International journal of oral and maxillofacial surgery·2022

Same author

Major colorectal resection is feasible using a new robotic surgical platform: the first report of a case series.

Techniques in coloproctology·2020

Same journal

CitM mediates hydroxycitrate (HCA) uptake: insights from heterologous expression in Escherichia coli, Bacillus subtilis mutant analysis and membrane topology prediction.

Biotechnology letters·2026

Same journal

Foliar and root absorption of LDH nanosheets loaded with dsRNAs efficiently silenced the expression of whitefly Bemisia tabaci Laccase 1 and Vitellogenin Receptor genes for their effective control.

Biotechnology letters·2026

Same journal

Morfo-anatomical insights into the germination and protocorm growth of the endangered Vanilla lindmaniana (Orchidaceae).

Biotechnology letters·2026

Same journal

Biosynthetic glycosylation as a critical structural determinant of antifungal activity in venturicidin A.

Biotechnology letters·2026

Same journal

Scaling up biomass production of Vishniacozyma victoriae and semi-commercial testing for post-harvest control of pome fruit disease.

Biotechnology letters·2026

Same journal

Efficient production of L-asparaginase using recombinant Pichia pastoris and strategy to eliminate glutaminase activity.

Biotechnology letters·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 7, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Recent advances and current challenges in CAR-T cell therapy.

R Joy¹, K Phair¹, R O'Hara¹

¹EnviroCORE, Department of Applied Science, South East Technological University, SETU Carlow, Kilkenny Road, Carlow, R93V960, Ireland.

Biotechnology Letters

|December 27, 2023

Summary

This summary is machine-generated.

Chimeric Antigen Receptor- T (CAR-T) cell therapy offers high response rates for certain blood cancers but faces challenges. Improving safety, effectiveness, and accessibility are key for its future implementation.

Keywords:

CAR-T cell therapy CAR-T cells Cancer Clinical trials

More Related Videos

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Experiment Videos

Last Updated: Jul 7, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Area of Science:

Oncology
Immunotherapy
Cellular Therapy

Background:

Immunotherapy, particularly Chimeric Antigen Receptor- T (CAR-T) cell therapy, represents a significant advancement in cancer treatment.
CAR-T therapy involves modifying a patient's own T cells to target and eliminate cancer cells, revolutionizing treatment approaches for certain malignancies.

Purpose of the Study:

To review recent advancements in CAR-T cell therapy.
To examine the current challenges and regulatory landscapes in the United States (US) and European Union (EU).
To provide critical insights for researchers and manufacturers navigating global market entry.

Main Methods:

Literature review of recent advancements in CAR-T cell therapy.
Analysis of regulatory frameworks in the US and EU.
Synthesis of data on clinical trial progress and outcomes.

Main Results:

CAR-T therapy demonstrates high response rates and potential for long-term remission in hematological malignancies.
Significant challenges persist, including high costs, adverse reactions, and limited efficacy against solid tumors.
Over 1231 CAR-T cell therapy clinical trials are underway globally, indicating rapid development.

Conclusions:

CAR-T cell therapy holds immense promise for cancer treatment.
Enhancing safety, effectiveness, and accessibility are crucial for widespread clinical implementation.
Navigating regulatory pathways is essential for global accessibility.